18F-fluorocholine positron emission tomography/computed tomography for early outcome prediction in metastatic castration-resistant prostate cancer patients treated with enzalutamide: A ...

Association of polymorphism in YB-1 regulating androgen receptor V7 expression with efficacy of androgen-deprivation therapy in metastatic prostate cancer. This is an ASCO Meeting Abstract from the ...

The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients. The Food and Drug Administration (FDA) has approved Tlando™ ...

SAN DIEGO -- Long-term testosterone therapy was associated with sustained reductions in weight for men with hypogonadism and class III obesity, a researcher reported. In registry data on 76 patients, ...

Please provide your email address to receive an email when new articles are posted on . The proportion of men who reported benefits 5 years after the T4DM trial was similar in the testosterone and ...

WASHINGTON--An industry-supported study of an oral testosterone replacement therapy (TRT), testosterone undecanoate (TU, brand name Jatenzo) finds it is an effective, long-term treatment for men with ...

MIAMI -- Oral testosterone replacement therapy (TRT) seemed safe and effective in men with testosterone deficiency, according to a meta-analysis. Among nine studies that looked at changes in serum ...

Results of an observational registry study of men with type 2 diabetes and hypogonadism (low testosterone) suggest that up to 12 years of testosterone injections every 3 months may improve glycemic ...

- Launched in 2020, JATENZO was the first oral softgel testosterone medicine approved in the US by the FDA in more than 60 years- JATENZO is an oral softgel testosterone undecanoate for testosterone ...

NEW YORK (Reuters Health) - A new oral testosterone undecanoate formulation can restore testosterone concentrations to normal in hypogonadal men, researchers report. "Effective as other testosterone ...

KYZATREX ® is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX ® is safe or effective in males younger than 18 years old. Improper use may affect bone growth ...